Abstract: Methods of increasing storage stability of lipidic nucleus nanocapsules comprising adding a monosaccharide cryoprotective agent into the aqueous dispersion of the nanocapsules while maintaining gentle stirring until the same dissolves totally. Afterwards, freezing said dispersion thus obtained at a temperature of not less than -40.degree. C. for about 2 to 4 hours, and the eliminating the water by heating progressively to a temperature of about 35.degree. C. at reduced pressure, whereby a stable lyophilized product is obtained. The obtained product can be conveniently reconstituted by adding water or a more complex aqueous solution thereto. The nanocapsules have use in medicine, pharmacy, cosmetics, chemical industry, agriculture, and veterinary science.

Abstract: The process comprises: (1) preparing a fine dispersion of droplets or particles which contain, or are formed, of a chemical or biologically active substance in a phase comprised of a solvent and a non solvent of the polymer forming the coating and, optionally, a surfactant or suspending agent; (2) preparing a phase which contains the coat-forming polymer dissolved in a miscible solvent in any relationship with the prior dispersion, (3) mixing both phases continuously while maintaining constant the relationship between the phases and the mixture volume, and simultaneously spraying the resultant mixture in an evaporation system with temperature and vacuum conditions which provide for the instantaneous evaporation of the solvent from the polymer, causing the deposition of the polymer around the particles or droplets. Applications to pharmacy, medicine, cosmetics, veterinary, chemical industry, agriculture are discussed.

Abstract: In one embodiment, a container including a bottom container closed at a bottom end and open at a top end and having a tubular neck, a top container open at a top end and closed at a bottom by a tearable seal, a flap extending radially out from an exterior of the top container so that the flap surrounds the neck of the bottom container, and a tubular sleeve having a bottom end and a top end, the bottom end defined by a beveled edge and the top end closed by a truncated cone, the bottom end of the tubular sleeve being sized and shaped to be received within the open end of the top container. The tubular neck has a peripheral edge containing a first set of stria, and an interior of the tubular neck has a plurality of sealing rings. The top container engages the sealing rings of the bottom container, and the flap surrounds the neck of the bottom container, when the top container is inserted into the interior of the tubular neck.

Abstract: It comprises: (1) preparing an aqueous phase containing surface active suspensor agents and, optionally, a chemically or biologically active chemical substance; (2) preparing an organic phase containing a biocompatible polymer or monomer and, optionally, a lipid or chemically or biologically active chemical substance; (3) mixing both phases in a continuous manner in a constant average phase-volume ratio, continuously removing a recently formed colloidal suspension; (4) continuously eliminating the solvent from the colloidal suspension; and (5) completely eliminating the organic solvent and part or all of the water in order to obtain the desired concentration of nanospheres or dry product.Application in biomedicine, pharmacy, medicine, cosmetics, chemical industry, agriculture, veterinary science, etc.

Abstract: A pharmaceutical vehicle which is a nanoemulsion is formulated using 0.1-10 % (w/v) of an oil; 0.1-10% (w/v) of a non-ionic surface active agent; a maximum of 0.01% (w/v) of benzalkonium chloride; a drug or a precursor or active substance; and optionally, one or more of the following components; isotonizing agents, viscosity modifying agents, stabilizers, buffers and/or antioxidants. The vehicle is prepared by emulsification of an aqueous phase which contains a non-ionic surface active agent with an organic phase containing dissolved therein an oil and the drug, drug precursor or active substance in an organic water miscible solvent and then totally removing by evaporation the organic solvent and part of the water up to the final desired volume. The vehicle is especially useful in ophthalmic preparations used to treat eye disorders and diseases.

Abstract: It comprises: 0.005-1.0% of trimethoprim or a pharmaceutically acceptable salt thereof: 0.01-0.3% of polymyxin or a pharmaceutically acceptable salt thereof: 0.001-5% of a steroidal or non-steroidal anti-inflammatory drug and, optionally, one or more ingredients selected from among isotonizing agents, pH buffers, viscosity modifying agents, wetting agents, chelating agents, anti-oxidants, preservatives and vehicles. The formulation has a pH between 4 and 8.5.It is applicable in the treatment of ophthalmic and otic infections accompanied by inflammation.

Abstract: This invention includes a pharmaceutically acceptable formulation of Diclofenac, Tobramycin, a solubility agent and, optionally, excipients, tonicifiers, buffers, viscosity modifying agents, preservatives, and chelating agents, at a pH from greater than 7.0 to about 9. The invention also discloses the use of this pharmaceutically acceptable formulation of an antibiotic and NSAIDs to treat eye and ear conditions accompanied by infection and inflammation.

Abstract: A dispenser for pharmaceutical solutions which includes membranes which are placed in a dropper of the dispenser and are used to achieve the flow of essentially all the active product and the retention of essentially all the preservative during pharmacological treatment. The membrane is coupled between two cylinder units on parts of the dropper, which remain in a relatively movable position, owing to the existence of a certain play between the cylinder units; or the cylinder units may be in a relatively fixed position, owing to the lack of such play. The cylinder unit may also be in a fixed position but with a membrane treated adequately so as to have a small area or "stain" that permits the flow of air.

Abstract: A pharmaceutical product container houses two separate substances. The container includes a bottom container having a first substance. The bottom container has an edge disposed at an open mouth thereof. A top container has a second substance. The top container has a frangible bottom wall. The top container has a flap extending radially outwardly. The flap includes an annular rib. The annular rib has a device for retaining the edge of the bottom container. The top container has a neck portion extending axially remote from the bottom wall. The neck has a helical thread to receive the cap. The neck includes a plurality of radially extending toothed projections about its perimeter. A tubular sleeve is disposed within the top container. The tubular sleeve is axially moveable with respect to the top container. The tubular sleeve has a first end and a second end.

Abstract: Ophthalmic product comprising nanocapsules, process for preparing it and application of the nanocapsules.The present invention relates to an ophthalmic product comprising nanocapsules, characterized by a central core of lipid nature surrounded by a polymeric membrane capable of adhering to biological tissues.The present invention also relates to its preparation and to the application of the nanocapsules for ophthalmic use.